«HIGHLIGHTS OF PRESCRIBING INFORMATION - WARNINGS AND PRECAUTIONS - These highlights do not include all the information needed to use Candida ...»
17.7 Reduced Growth Velocity Patients should be informed that orally inhaled corticosteroids, including mometasone furoate inhalation powder, may cause a reduction in growth velocity when administered to pediatric patients.
Physicians should closely follow the growth of children and adolescents taking corticosteroids by any route [see Warnings and Precautions (5.8)].
17.8 Use Daily for Best Effect Patients should be advised to use ASMANEX TWISTHALER at regular intervals, since its effectiveness depends on regular use. Maximum benefit may not be achieved for 1 to 2 weeks or longer after starting treatment. If symptoms do not improve in that time frame or if the condition worsens, patients should be instructed to contact their physician.
17.9 Instructions for Use Patients should be instructed to record the date of pouch opening on the cap label and discard the inhaler 45 days after opening the foil pouch or when the dose counter reads “00” and the final dose has been inhaled, whichever comes first. The inhaler should be held upright while removing the cap.
The medication should be taken as directed, breathing rapidly and deeply, and patients should not breathe out through the inhaler. The mouthpiece should be wiped dry and the cap replaced immediately following each inhalation and rotated fully until the click is heard. Rinsing of mouth after inhalation is advised. Patients should store the unit as instructed. The dose counter displays the doses remaining. When the dose counter indicates zero, the cap will lock and the unit must be discarded.
Patients should be advised that if the dose counter is not working correctly, the unit should not be used and it should be brought to their physician or pharmacist.
MSD International GmbH (Singapore Branch) Singapore 638030, Singapore For patent information: www.merck.com/product/patent/home.html Copyright © 2008, 2011 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.